Predicting Response to Vismodegib in Locally Advanced Basal Cell Carcinoma

Description

In a recent letter to the editor, Maria Concetta Fargnoli, MD, of L’Aquila, L’Aquila, Italy, and colleagues shared their real-world, multicenter, retrospective study findings aimed at evaluating the clinical determinants of complete response to the Hedgehog pathway inhibitor vismodegib in patients with locally advanced basal cell carcinoma. Their work, published in the Journal of the European Academy of Dermatology and Venereology, showed that dosing changes compromised complete response rates.